347 related articles for article (PubMed ID: 25023731)
21. Gene therapy for hypercholesterolemia: sweet dreams and flying machines.
Huff MW; Assini JM; Hegele RA
Circ Res; 2014 Aug; 115(6):542-5. PubMed ID: 25170090
[No Abstract] [Full Text] [Related]
22. The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.
Susan-Resiga D; Girard E; Kiss RS; Essalmani R; Hamelin J; Asselin MC; Awan Z; Butkinaree C; Fleury A; Soldera A; Dory YL; Baass A; Seidah NG
J Biol Chem; 2017 Feb; 292(5):1573-1590. PubMed ID: 27998977
[TBL] [Abstract][Full Text] [Related]
23. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M
J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
[TBL] [Abstract][Full Text] [Related]
24. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
Poirier S; Mayer G; Benjannet S; Bergeron E; Marcinkiewicz J; Nassoury N; Mayer H; Nimpf J; Prat A; Seidah NG
J Biol Chem; 2008 Jan; 283(4):2363-72. PubMed ID: 18039658
[TBL] [Abstract][Full Text] [Related]
25. Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
Lu H; Howatt DA; Balakrishnan A; Graham MJ; Mullick AE; Daugherty A
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1753-7. PubMed ID: 27470509
[TBL] [Abstract][Full Text] [Related]
26. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
27. Nonclinical Pharmacology/Toxicology Study of AAV8.TBG.mLDLR and AAV8.TBG.hLDLR in a Mouse Model of Homozygous Familial Hypercholesterolemia.
Greig JA; Limberis MP; Bell P; Chen SJ; Calcedo R; Rader DJ; Wilson JM
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):28-38. PubMed ID: 28319445
[TBL] [Abstract][Full Text] [Related]
28. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
Tada H; Kawashiri MA; Yoshida T; Teramoto R; Nohara A; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
Circ J; 2016; 80(2):512-8. PubMed ID: 26632531
[TBL] [Abstract][Full Text] [Related]
29. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
Awan Z; Baass A; Genest J
Clin Chem; 2014 Nov; 60(11):1380-9. PubMed ID: 25248569
[TBL] [Abstract][Full Text] [Related]
30. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.
Le QT; Blanchet M; Seidah NG; Labonté P
J Biol Chem; 2015 Sep; 290(38):23385-400. PubMed ID: 26195630
[TBL] [Abstract][Full Text] [Related]
31. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
32. Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with familial hypercholesterolemia in Malaysia.
Lye SH; Chahil JK; Bagali P; Alex L; Vadivelu J; Ahmad WA; Chan SP; Thong MK; Zain SM; Mohamed R
PLoS One; 2013; 8(4):e60729. PubMed ID: 23593297
[TBL] [Abstract][Full Text] [Related]
33. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
[TBL] [Abstract][Full Text] [Related]
34. Non-Clinical Study Examining AAV8.TBG.hLDLR Vector-Associated Toxicity in Chow-Fed Wild-Type and LDLR
Greig JA; Limberis MP; Bell P; Chen SJ; Calcedo R; Rader DJ; Wilson JM
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):39-50. PubMed ID: 28319449
[TBL] [Abstract][Full Text] [Related]
35. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
[TBL] [Abstract][Full Text] [Related]
36. Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice.
Miyazawa H; Tabeta K; Miyauchi S; Aoki-Nonaka Y; Domon H; Honda T; Nakajima T; Yamazaki K
Lipids Health Dis; 2012 Sep; 11():121. PubMed ID: 22992388
[TBL] [Abstract][Full Text] [Related]
37. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
Canuel M; Sun X; Asselin MC; Paramithiotis E; Prat A; Seidah NG
PLoS One; 2013; 8(5):e64145. PubMed ID: 23675525
[TBL] [Abstract][Full Text] [Related]
38. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
[TBL] [Abstract][Full Text] [Related]
39. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
[TBL] [Abstract][Full Text] [Related]
40. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
Stein EA; Honarpour N; Wasserman SM; Xu F; Scott R; Raal FJ
Circulation; 2013 Nov; 128(19):2113-20. PubMed ID: 24014831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
